Actively Recruiting

Phase 4
Age: 20Years - 45Years
FEMALE
ID07288801

Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial

Led by Nishtar Medical University · Updated on 2025-12-17

146

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial investigates whether giving vitamin D supplements to pregnant women who had pre-eclampsia in a previous pregnancy can help prevent the condition from returning. The study aims to find out if vitamin D reduces the chance of recurrent pre-eclampsia in this group of women. Pregnant women attending the antenatal clinic at Nishtar Hospital Multan are invited to participate in this research. Participants will be randomly assigned to one of two groups. One group will take 4,000 IU of oral vitamin D daily until 36 weeks of pregnancy. The other group will receive a placebo pill that looks, tastes, and feels the same but contains no vitamin D. Each woman will visit the clinic every two weeks during the study period. During each visit, blood pressure will be checked, and if it reaches 140/90 mmHg or higher, a urine test will be done to check for protein, which helps identify pre-eclampsia. If pre-eclampsia is diagnosed, standard care will be provided and recorded. The main outcome is to compare how many women in each group develop recurrent pre-eclampsia by 36 completed weeks of pregnancy.

CONDITIONS

Brief Title

Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women

Who Can Participate

Age: 20Years - 45Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Gestational age of 20 weeks or more (based on last menstrual period)
  • Past medical history of pre-eclampsia
  • Female participants aged between 20 and 45 years
Not Eligible

You will not qualify if you...

  • Pre-existing hypertension, cardiac diseases, renal disease, or thyrotoxicosis as noted in medical history or records
  • Women presenting with intra-uterine fetal death in the current pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - From enrollment until 36 completed weeks of gestation

Participants take either vitamin D or placebo orally once daily until 36 weeks of gestation.

Regular visits as per study schedule until 36 weeks of gestation

Trial Site Locations

Total: 1 location

1

Nishtar Medical University and Hospital

Multan, Punjab Province, Pakistan, 60000

Actively Recruiting

Loading map...

Research Team

T

Tehseen A Principal Investigator, MBBS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Development and Validation of a Prediction Model for Adverse...

Aplastic Anemia

Actively Recruiting

1 location

A Randomized, Placebo-controlled Trial of Dapagliflozin for ...

Gestational Hypertension

Actively Recruiting

1 location

A Repository to Study Host-Microbiome Interactions in Health...

Healthy Controls

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here